Nuo Therapeutics, Inc. financial data

Symbol
AURX on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
8285 El Rio, Suite 150, Houston, Texas
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CYTOMEDIX INC (to 10/8/2014), AUTOLOGOUS WOUND THERAPY INC (to 4/10/2000), AUTOLOGOUS WOUND TRERAPY INC (to 3/23/2000)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 171 % -68.8%
Quick Ratio 30.3 % -31.6%
Debt-to-equity 138 % +338%
Return On Equity -471 % -230%
Return On Assets -198 % -82.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.2M shares +5.84%
Common Stock, Shares, Outstanding 44.2M shares +5.84%
Entity Public Float 35.9M USD +102%
Common Stock, Value, Issued 4.42K USD +5.84%
Weighted Average Number of Shares Outstanding, Basic 44.2M shares +5.84%

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -3.02M USD +17.3%
Nonoperating Income (Expense) 465 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.17M USD +0.01%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -3.02M USD +17.2%
Earnings Per Share, Basic -0.08 USD/shares +11.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 366K USD -70.7%
Accounts Receivable, after Allowance for Credit Loss, Current 230K USD +71.3%
Inventory, Net 211K USD -0.26%
Assets, Current 981K USD -46.4%
Property, Plant and Equipment, Net 41.3K USD -24.1%
Operating Lease, Right-of-Use Asset 220K USD -34.7%
Assets 1.24M USD -44%
Accounts Payable, Current 486K USD +14.3%
Accrued Liabilities, Current 215K USD +51.9%
Liabilities, Current 761K USD +17.3%
Operating Lease, Liability, Noncurrent 148K USD -36.6%
Liabilities 909K USD +3.01%
Retained Earnings (Accumulated Deficit) -30.6M USD -11%
Stockholders' Equity Attributable to Parent 333K USD -75.1%
Liabilities and Equity 1.24M USD -44%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -562K USD +29.3%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 44.2M shares +5.84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -562K USD +29.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 366K USD -71.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.21K USD +63.7%
Deferred Tax Assets, Valuation Allowance 41.3M USD -0.91%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 41.3M USD -0.91%
Operating Lease, Liability 208K USD -34%
Depreciation 15K USD +37.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 262K USD -30.9%
Property, Plant and Equipment, Gross 455K USD +0.42%
Operating Lease, Liability, Current 60.3K USD -26.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 82.7K USD +3.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 80.3K USD -28.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Income Tax Expense (Benefit) -381K USD -124%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 53.7K USD -13.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 21.3K USD -74.3%
Deferred Tax Assets, Operating Loss Carryforwards 40.9M USD -0.77%
Deferred Federal Income Tax Expense (Benefit) -360K USD +9.02%
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 21.3K USD -74.3%
Additional Paid in Capital 31M USD +6.98%
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 0 USD
Share-based Payment Arrangement, Expense 3.08K USD +27.3%
Deferred State and Local Income Tax Expense (Benefit) -20.2K USD -101%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%